Clinical Trial Update: Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial evaluated the safety of an intradermal GFD fusion protein for cat allergy; the study was terminated and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cat Allergy

Drugs mentioned

• GFD (intradermal human Fcγ1-Fel d1 fusion protein)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cat Allergy | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2014-02-20